Enanta Pharmaceuticals | ENTA - Ebitda


Enanta Pharmaceuticals reported $-36.06M in EBITDA for its fiscal quarter ending in June of 2023.





Ebitda Change Date
AbbVie USD 5.37B 1.85B Dec/2025
Amgen USD 5.14B 775M Dec/2025
Anika Therapeutics USD 4.54M 3.67M Dec/2025
Arrowhead Research USD 57.17M 7.03M Dec/2025
AstraZeneca USD 5.67B 1.29B Mar/2026
BioCryst Pharmaceuticals USD 51.7M 30.14M Sep/2025
Biogen USD 649.7M 76.5M Mar/2026
Bristol-Myers Squibb USD 2.88B 1.36B Dec/2025
Gilead Sciences USD 3.02B 1.01B Dec/2025
GlaxoSmithKline GBP 2.77B 1.65B Mar/2026
Halozyme Therapeutics USD 219.57M 197.66M Mar/2026
Heron Therapeutics USD -3.88M 5.63M Sep/2024
Immunic USD -22.78M 753K Jun/2024
Incyte USD 367.97M 46.53M Mar/2026
Insmed USD -148.3M 165.88M Mar/2026
Ionis Pharmaceuticals USD -200.02M 42.89M Dec/2025
J&J USD 8.27B 1.08B Mar/2026
Karyopharm Therapeutics USD -26.2M 1.83M Sep/2024
Ligand Pharmaceuticals USD 66.78M 83.54M Dec/2025
Merck USD 6.3B 2.09B Dec/2025
Neurocrine Biosciences USD 193.3M 25.1M Mar/2026
Novartis USD 6.48B 1.19B Jun/2026
Novavax USD 19.36M 190.79M Dec/2025
Pfizer USD 5.99B 5.23B Mar/2026
PTC Therapeutics USD -70.99M 91.62M Dec/2025
Roche Holding CHF 13.43B 744M Jun/2026
Sarepta Therapeutics USD -252.2M 84.16M Dec/2025
Vertex Pharmaceuticals USD 1.19B 195.3M Mar/2026